Micromet Inc. (MITI) Makes Solid Headway in Development of New BiTE Antibody Platform
In some markets, companies rate an investment a “buy” when it meets a generally accepted set of parameters. In a certain sense, this method of investing in a market reduces risk to a proven and generally accepted formula. Every now and again, however, a new process comes along that may alter this generally accepted strategy. If an investor can find a company that may have something new in its research pipeline, they may want to look closer and consider breaking this strategy for a shot at a nice profit. Micromet Inc., a development stage biopharmaceuticals company, works to develop and…